2025 ESMO GI | 中国智慧闪耀日内瓦：入选研究一览

前言

胃食管癌

1 摘要号：394P

研究名称（英文）：Reactive cutaneous capillary endothelial proliferation in esophageal squamous cell carcinoma patients treated with camrelizumab-based therapy: a pooled analysis of two Phase 3 trials

讲者：骆卉妍 | 中山大学肿瘤防治中心

2 摘要号：396P

研究名称（英文）：A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy

讲者：Hung-Yang Kuo | 台湾大学医学院附设医院

3 摘要号：399P

研究名称（英文）：ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1-SREBP1 Mediated Metabolic Reprogramming

讲者：Xinyue Ma | 山东大学齐鲁医院

4 摘要号：418P

研究名称（英文）：Real-world Outcomes of First-line Nivolumab for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Multicenter, Retrospective, Observational Study

讲者：邱红 | 华中科技大学同济医学院附属同济医院

5 摘要号：419P

研究名称（英文）：Real-world Treatment Pattern and Biomarker Testing Landscape of Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC) in China (SURPASS Study)

讲者：Rongrui Liu | 中国人民解放军总医院

6 摘要号：424P

研究名称（英文）：Chemotherapy (SOX) plus Tisleizumab in Gastric cancer patients with liver metastasis: the first report from a multi-center phase II study

讲者：康牧星 | 浙江大学医学院附属第二医院

7 摘要号：430P

研究名称（英文）：Decoding the Responsive and Resistant Features to the Claudin18.2-specific CAR-T cell CT041 in Gastric Cancer: An Exploratory Biomarker Analysis of the Phase 1 Clinical Trial

讲者：彭昊昕 | 北京大学肿瘤医院

8 摘要号：436P

研究名称（英文）：Hepatic resection improves the prognosis of gastric cancer liver metastasis patients with resected primary lesions

讲者：Yun Feng | 复旦大学附属肿瘤医院

肝胆胰肿瘤

1 摘要号：LBA2

研究名称（英文）：TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + Bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC)

讲者：韩国宏 | 西安国际医学中心医院

2 摘要号：149MO

研究名称（英文）：Irpagratinib (ABSK-011) plus Atezolizumab in First-line (1L) and Immune Checkpoint Inhibitors (ICIs) Treated Advanced Hepatocellular Carcinoma (HCC) with FGF19 Overexpression (+): Updated Results of the Phase 2 ABSK-011-201 Study

讲者：程琪 | 华中科技大学同济医学院附属同济医院

3 摘要号：150MO

研究名称（英文）：Safety results from the Phase 3b SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosis

讲者：Stephen L. Chan | 香港中文大学

4 摘要号：157P

研究名称（英文）：Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment in Chinese patients with unresectable/advanced hepatocellular carcinoma (HCC): CheckMate 9DW expanded analyses

讲者：秦叔逵 | 中国药科大学附属南京天印山医院

5 摘要号：183P

研究名称（英文）：Comparison of the prognostic value of NLR with PLR, LMR, SII, and PNI in HCC patients undergoing cryoablation and its application in the best applicable population

讲者：李家平 | 中山大学附属第一医院

6 摘要号：195P

研究名称（英文）：Bioinformatics and system biology approach to identify the influences among COVID-19, cirrhosis and hepatocellular carcinoma

讲者：Xianxiang Chen | 广西医科大学第一附属医院

7 摘要号：203eP

研究名称（英文）：Cell-free DNA (cfDNA) Biomarkers and AI Models for Early Detection of Liver Cancer: A Systematic Review and Meta-Analysis

讲者：Minh Le | 台北医学大学

8 摘要号：206eP

研究名称（英文）：Prognostic Influence of Baseline ALBI Grade on Treatment Outcomes in Hepatocellular Carcinoma Patients Receiving Lenvatinib

讲者：商昌珍 | 中山大学孙逸仙纪念医院

9 摘要号：209eP

研究名称（英文）：RPL41 Promotes HCC Metastasis Via Transcription Factors RUNX2-Mediated EMT Mechanism

讲者：Zheng Hua | 重庆大学附属沙坪坝医院

10 摘要号：302P

研究名称（英文）：Surufatinib plus gemcitabine and nab-paclitaxel for neoadjuvant therapy in resectable and borderline resectable pancreatic cancer

讲者：高松 | 天津市肿瘤医院

11 摘要号：313P

研究名称（英文）：ABHD17C-mediated S-depalmitoylation of BCL6B enhances CD24 transcription to resist macrophage phagocytosis in pancreatic cancer

讲者：Yalu Zhang | 中国科学技术大学附属第一医院

12 摘要号：317P

研究名称（英文）：Tumor-Microenvironment-on-Chip: A Real-Time Window into Immunotherapy Efficacy under Heterogeneity

讲者：Chiao-Min Lin | 台湾清华大学

13 摘要号：358P

研究名称（英文）：Comparative Effectiveness of Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancer: A Single-Center Retrospective Cohort Study

讲者：Wen-Ying Lin | 台北荣民总医院

结直肠癌

1 摘要号：LBA1

研究名称（英文）：Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Non-Metastatic Colorectal Cancer: Interim Analysis of FIND Trial

讲者：彭俊杰 | 复旦大学附属肿瘤医院

2 摘要号：11P

研究名称（英文）：NALIRIFOX Plus Targeted Therapy as First-Line Treatment for Metastatic Colorectal Cancer: A Phase I Study

讲者：Haojie Zhou | 复旦大学附属中山医院

3 摘要号：49P

研究名称（英文）：A multicentre propensity score matched analysis comparing maintenance strategies and treatment-break after first-line induction therapy for metastatic colorectal cancer

讲者：Connie Ka Yan Lai | 伊利沙伯医院

4 摘要号：65P

研究名称（英文）：BETTER Study: An Open-Label, Single-Arm Trial of Tislelizumab, Bevacizumab, TAS102, and SBRT as Third-Line Therapy for MSS/pMMR Metastatic Colorectal Cancer

讲者：张群 | 南京鼓楼医院

5 摘要号：98P

研究名称（英文）：A novel risk-stratification model with molecular markers for predicting early colorectal cancer invasion depth

讲者：Bing Li | 复旦大学

6 摘要号：130eP

研究名称（英文）：From Evidence to Practice: A Multicenter Real-World Study and Meta-Analysis of Immunotherapy in MSS/MSI-L Colorectal Cancer

讲者：Yue Gou | 中南大学

7 摘要号：131eP

研究名称（英文）：Efficacy and safety of triple-therapy with bevacizumab, oxaliplatin, with irinotecan for metastatic colorectal cancer failed with previous fluorouracil-centered treatment

讲者：韩璐 | 中国人民解放军总医院第五医学中心

8 摘要号：139eP

研究名称（英文）：Real-World Practice of MSI/MMR Testing and Treatment Patterns in Colorectal Cancer: A Nationwide Survey in China (SUMMER Study)

讲者：王正航 | 北京大学肿瘤医院

9 摘要号：146TiP

研究名称（英文）：MIRACLE3: Phase II study of Ivonescimab plus radiotherapy and chemotherapy as first-line treatment in MSS colorectal cancer patients with unresectable liver/lung metastases — Trial in progress

讲者：李心翔 | 复旦大学附属肿瘤医院

10 摘要号：224P

研究名称（英文）：Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: a prospective, randomized controlled trial (SPRING-01)

讲者：Feng Tian | 山东第一医科大学附属省立医院

11 摘要号：226P

研究名称（英文）：Adebrelimab Combined with Short-Course Radiotherapy and CAPOX as Total Neoadjuvant Therapy for pMMR Locally Advanced Rectal Cancer: Interim Results

讲者：靖昌庆 | 山东第一医科大学附属省立医院

12 摘要号：229P

研究名称（英文）：Randomized study of neoadjuvant chemoradiotherapy with or without intensification with FOLFOXIRI for high-risk locally advanced rectal cancer - clinical and quality of life analysis (NCT03997435)

讲者：Ka Yan Lai | 伊利沙伯医院

胃肠道罕见肿瘤

1 摘要号：219eP

研究名称（英文）：

Prognostic Factors for Metastatic Gastrointestinal Stromal Tumors Treated with Cytoreductive Surgery: A Retrospective Cohort Study

讲者：Haidong Zhang | 四川大学华西医院

其他

1 摘要号：495P

研究名称（英文）：Optimising Chemotherapy Tolerability in Older Gastrointestinal Cancer Patients with Initial Dose Reduction

讲者：Wendy W. Chan | 香港大学李嘉诚医学院

2 摘要号：499P

研究名称（英文）：Association of TACR1 genotype and response to olanzapine-containing antiemetic prophylaxis for chemotherapy

讲者：Winnie Yeo | 香港中文大学

3 摘要号：505eP

研究名称（英文）：Real World Efficacy of Anlotinib in Bevacizumab-Treated Gastrointestinal Cancers

讲者：陈锦章 | 南方医科大学南方医院

备注：

如有遗漏或任何问题，请给我们留言~

撰写：Aurora

审核：Babel

排版：Aurora

执行：Aurora

医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。

本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。